Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in Essential Thrombocythemia or Polycythemia Vera
NCT01243073Phase 2Completed
- Sponsor
- Geron Corporation
- Start
- Dec 2010
- Primary completion
- Oct 2013
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of imetelstat in essential thrombocythemia (ET) and polycythemia vera (PV), sponsored by Geron Corporation. Primary endpoints: Hematologic Response at 12 months and Maintenance of Hematocrit at 12 months. Started Dec 2010; status: completed.
02
Drugs
imetelstat
03
Conditions
essential thrombocythemia (ET)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT01243073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01243073.